Hsbc Holdings PLC Lowers Stock Position in Enovis Corporation $ENOV

Hsbc Holdings PLC decreased its holdings in shares of Enovis Corporation (NYSE:ENOV) by 19.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 280,716 shares of the company’s stock after selling 67,115 shares during the period. Hsbc Holdings PLC’s holdings in Enovis were worth $7,575,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Arax Advisory Partners acquired a new stake in shares of Enovis in the 4th quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares during the period. Danske Bank A S acquired a new stake in Enovis in the third quarter valued at $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in Enovis in the third quarter valued at $80,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have bought 4,200 shares of company stock valued at $92,084. 2.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Wells Fargo & Company lowered their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Enovis Stock Up 2.4%

ENOV opened at $22.54 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -1.13 and a beta of 1.38. Enovis Corporation has a one year low of $20.55 and a one year high of $36.82. The business’s fifty day moving average is $23.58 and its two-hundred day moving average is $24.06.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.